Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.

Autor: Sandmark J; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden jenny.sandmark@astrazeneca.com., Tigerström A; Precision Medicine BioPharmaceuticals, Precision Medicine, Oncology R&D, AstraZeneca, Gothenburg, Sweden., Akerud T; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Althage M; Translational Science and Experimental Medicine, Early CVRM Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Antonsson T; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Blaho S; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Bodin C; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Boström J; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Chen Y; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Dahlén A; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Eriksson PO; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Evertsson E; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Fex T; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Fjellström O; Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Gustafsson D; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Herslöf M; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hicks R; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Jarkvist E; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Johansson C; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Kalies I; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Karlsson Svalstedt B; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kartberg F; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Legnehed A; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Martinsson S; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Moberg A; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Ridderström M; Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Rosengren B; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Thelin A; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Vinblad J; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wellner AU; Medicinal Chemistry, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Xu B; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Östlund-Lindqvist AM; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Knecht W; Bioscience Cardiovascular, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden Wolfgang.Knecht@biol.lu.se.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2020 Apr 10; Vol. 295 (15), pp. 5136-5151. Date of Electronic Publication: 2020 Mar 04.

Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice.

Autor: Lundåsen T; Karolinska Institute, Department of Endocrinology, Metabolism and Diabetes, and Molecular Nutrition Unit, Center for Biosciences, NOVUM, Karolinska University Hospital Huddinge, Stockholm, Sweden., Andersson EM, Snaith M, Lindmark H, Lundberg J, Östlund-Lindqvist AM, Angelin B, Rudling M

Publikováno v: PloS one [PLoS One] 2012; Vol. 7 (5), pp. e37787. Date of Electronic Publication: 2012 May 25.